Mercy Bio Technology

Mercy BioAnalytics is a biotechnology company dedicated to the early detection of cancer through its proprietary Mercy Halo™ liquid biopsy platform. The company's technology focuses on extracellular vesicles (EVs), which are microscopic particles released by cells that carry molecular information about their origin. By co-detecting multiple cancer-specific biomarkers on the surface of individual EVs, the Mercy Halo™ platform provides high sensitivity and specificity for early-stage disease. The company's lead diagnostic programs are currently focused on the early detection of ovarian and lung cancers. Mercy BioAnalytics aims to transform cancer care by providing accessible, blood-based screening tools that can identify malignancies when they are most treatable.